A novel bispecific affitoxin simultaneously targeting E7 of HPV16/18 types: superior anti-tumor activity and EMT reversal in HPV-driven cervical cancer therapy
This work has developed a bispecific affitoxin that simultaneously targets HPV16- and HPV18-type CC cells, with a significant dual-functional advantage, combining the targeted inhibitory of the affibody with the cytotoxicity of the toxin molecule. Our research offers a novel design and approach for targeted therapy in HPV-driven cervical cancer.
Authors
- Shu Feng (ORCID: https://orcid.org/0000-0003-2346-5778)
- Lifang Zhang (ORCID: https://orcid.org/0000-0002-8382-4528)
- Xin Jing (ORCID: https://orcid.org/0000-0002-4671-3706)
- Zhizhong Xie (ORCID: https://orcid.org/0000-0003-3365-0379)
- Wenshu Li
- Yanheng Li
- Kairong Wan
- YU Li-jun (ORCID: https://orcid.org/0000-0001-8366-5179)
- Junze Wu (ORCID: https://orcid.org/0009-0000-4909-0172)
Institutions
- Universitat de València (ES)
- Wenzhou Medical University (CN)
- Universitat Politècnica de València (ES)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1186/s12967-025-06971-9
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China